Ipilimumab

Generic Name
Ipilimumab
Brand Names
Yervoy
Drug Type
Biotech
Chemical Formula
-
CAS Number
477202-00-9
Unique Ingredient Identifier
6T8C155666
Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication

Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions
Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
First Line Chemotherapy
Clinical Trials
Related News

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

First Posted Date
2021-03-04
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT04781855
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

First Posted Date
2021-02-12
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT04751370
Locations
🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

Logan Health Medical Center, Kalispell, Montana, United States

🇺🇸

Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 213 locations

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

First Posted Date
2021-01-14
Last Posted Date
2024-11-04
Lead Sponsor
Andrew J. Armstrong, MD
Target Recruit Count
43
Registration Number
NCT04709276
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

First Posted Date
2021-01-06
Last Posted Date
2024-10-08
Lead Sponsor
Carlo Contreras
Target Recruit Count
36
Registration Number
NCT04697576
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

First Posted Date
2020-12-07
Last Posted Date
2024-05-23
Lead Sponsor
Jason J. Luke, MD
Target Recruit Count
2
Registration Number
NCT04655157
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Drug: Ipilimumab
First Posted Date
2020-11-19
Last Posted Date
2023-03-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
3
Registration Number
NCT04635735
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

First Posted Date
2020-11-06
Last Posted Date
2022-10-26
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
40
Registration Number
NCT04620200
Locations
🇳🇱

NKI-AVL, Amsterdam, Noord Holland, Netherlands

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

First Posted Date
2020-11-02
Last Posted Date
2024-07-19
Lead Sponsor
Inge Marie Svane
Target Recruit Count
5
Registration Number
NCT04611126
Locations
🇩🇰

National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

First Posted Date
2020-10-30
Last Posted Date
2024-04-02
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
9
Registration Number
NCT04610658
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Advent Health - Celebration, Kissimmee, Florida, United States

Surgical Nivolumab And Ipilimumab For Recurrent GBM

First Posted Date
2020-10-28
Last Posted Date
2024-07-16
Lead Sponsor
Patrick Wen, MD
Target Recruit Count
63
Registration Number
NCT04606316
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy